Document is current
Any future updates will be listed below
-
Authors
Simon, Sylvain https://orcid.org/0000-0001-5985-3946
Bugos, Grace
Prins, Rachel https://orcid.org/0000-0002-3973-9406
Rajan, Anusha https://orcid.org/0000-0002-0036-4301
Palani, Arulmozhi
Heyer, Kersten
Stevens, Andrew https://orcid.org/0000-0002-3015-1374
Zeng, Longhui
Thompson, Kirsten A. https://orcid.org/0000-0001-9388-9539
Atilla, Pinar A.
Price, Jason P.
Kluesner, Mitchell G.
Jaeger-Ruckstuhl, Carla A.
Shabaneh, Tamer B.
Olson, James M.
Su, Xiaolei
Riddell, Stanley R. https://orcid.org/0000-0002-4688-9920
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01 CA114536)
U.S. Department of Health & Human Services | National Institutes of Health (P01 CA18029)
Leukemia and Lymphoma Society (SCOR 1023-20)
Leukemia and Lymphoma Society (SCOR 1023-20)
Leukemia and Lymphoma Society (3405-21)
Bristol-Myers Squibb (SRA220501)
- License Information
-
More Information
Article History
Received: 2 October 2024
Accepted: 7 February 2025
First Online: 17 March 2025
Competing interests
: S.S., G.B. and S.R.R. are inventors on a patent (FHCC: 21-126-WO-PCT, app. no. PCT/US2023/066466, ‘Compositions and methods for cellular immunotherapy’) filed by the Fred Hutchinson Cancer Center and related to this work. S.R.R. is a founder of, has served as an advisor for and has patents licensed to Juno Therapeutics, a Bristol Myers Squibb company. S.R.R. is a founder of and holds equity in Lyell Immunopharma and Outpace Bio and has served on advisory boards for Lyell Immunopharma, Outpace Bio, AstraZeneca, ErVaccine, Adaptive Biotechnologies and Nohla. The other authors declare no competing interests.
